Cedric Gouedard , PhD, Marie Curie Postdoctoral Fellow
Address
Institute of Biological Research and Biotechnology (IBRB),
National Hellenic Research Foundation (NHRF)
48 Vassileos Constantinou Ave., 116 35 Athens, Greece
Telephone: +30.210.7273.742
Fax: +30.210.7273.677
e-mail: gouedard
Degrees 2000: Master of Pharmacy (Paris 11 University)
Master of Sciences in Toxicology (Paris 5 University) 2004: PhD in Molecular Toxicology (Paris 5 University)
Research experience 2000-2004: PhD student, INSERM UMR-S 490, Paris, France 2004-2005: Postdoctoral fellow, NHRF, IBRB, Molecular Endocrinology Programme
Research interests
His PhD research was in the field of gene regulation, especially mediated by nuclear receptors. His project was to identify regulatory pathways of the PON-1 gene encoding paraoxonase-1, an enzyme displaying protective effects against cardiovascular disease and organophosphates intoxications.
His current research focuses on the role played by growth factors receptors signalling on the transcriptional activity of nuclear receptors. This work is supported by a EU ''Marie Curie Development Host Fellowship'' (HPMD-CT-2001-00116).
Publications
1- Janel N, Robert K, Demuth K, Gouedard C, Barouki R, Chasse JF. Inverse correlation between phenylacetate hydrolase activity of the serum PON1 protein and homocysteinemia in humans. Thromb Haemost. 2005 Jan;93(1):182-3
2- Gouedard C, Barouki R, Morel Y. Induction of the Paraoxonase-1 Gene Expression by Resveratrol. Arterioscler Thromb Vasc Biol. 2004 Dec;24(12):2378-83
3- Janel N, Robert K, Chabert C, Ledru A, Gouedard C, Barouki R, Delabar JM, Chasse JF. Mouse liver paraoxonase-1 gene expression is downregulated in hyperhomocysteinemia. Thromb Haemost. 2004 Jul;92(1):221-2.
4- Gouedard C, Barouki R, Morel Y. Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. Mol Cell Biol. 2004 Jun;24(12):5209-22.
5- Gouedard C, Koum-Besson N, Barouki R, Morel Y. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol Pharmacol. 2003 Apr;63(4):945-56.